# Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
Canonical URL: https://biopharmsignal.com/news/YMAB/y-mabs-announces-update-to-national-comprehensive-cancer-networkr-nccnr-clinical-practice-guidelines-in-oncology-for-neuroblastoma-to-include-naxitamab-gqgk-danyelzar
Ticker: YMAB
Company: Y-mAbs
Source: Y-mAbs
Published: 2025-05-07 11:05 EST
Original Source URL: https://ir.ymabs.com
## Summary

PRINCETON, N.J. , May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the

## Article Body
PRINCETON, N.J. , May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the
## Recent Company News
- 2025-09-16 12:41 EST — [SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics](https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-completes-acquisition-of-y-mabs-therapeutics) — Source: Y-mAbs
- 2025-08-08 10:35 EST — [Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/YMAB/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-developments) — Source: Y-mAbs
- 2025-08-07 11:30 EST — [Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025](https://biopharmsignal.com/news/YMAB/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025) — Source: Y-mAbs
- 2025-08-05 12:30 EST — [SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics](https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics) — Source: Y-mAbs
- 2025-05-28 10:35 EST — [Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline](https://biopharmsignal.com/news/YMAB/y-mabs-hosts-virtual-radiopharmaceutical-randd-update-highlighting-clinical-progress-and-expanded-pipeline) — Source: Y-mAbs
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)